^
    Back
    Association details:
    Biomarker:EGFR exon 19 deletion + EGFR T790M
    Cancer:Non Small Cell Lung Cancer
    Drug:Gilotrif (afatinib) (pan-HER inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2021
    Title:

    1223P - Sequential afatinib (afa) and osimertinib (osi) in patients (pts) with advanced EGFR mutation-positive (EGFRm+) NSCLC who acquire the T790M resistance mutation: A non-interventional cohort study (UpSwinG)

    Published date:
    09/13/2021
    Excerpt:
    ...pts with EGFRm+ NSCLC (Del19 or L858R) treated with 1st-line afa/2nd-line osi in regular clinical practice (n = 191; all T790M+)...ORR with afa and osi was 74% and 45%....These data support the previous GioTag study and show encouraging activity of sequential afa/osi in pts with EGFRm+ NSCLC and acquired T790M.
    Trial ID:
    UpSwinG